Main Uses of Alsucral

Alsucral contains the active ingredient sucralfate, which is primarily used to treat and manage acid-related disorders in the upper gastrointestinal tract. Unlike medications that reduce the production of stomach acid, Alsucral acts as a local mucosal protective agent.

Treatment of Peptic Ulcers

The primary application of Alsucral is in the treatment of active duodenal ulcers. It is also utilized for the management of gastric (stomach) ulcers. The medication works by forming a physical barrier over the ulcerated tissue, protecting the area from the digestive actions of stomach acid, pepsin, and bile salts. This protective coating allows the underlying tissue to heal more effectively.

Prevention of Ulcer Recurrence

Beyond treating active ulcers, Alsucral is used as maintenance therapy for patients who have recently healed from a duodenal ulcer. In this capacity, it helps to reduce the risk of the ulcer returning after the initial healing phase has been completed.

Management of Gastritis

Alsucral may be used to treat chronic gastritis, an inflammation of the stomach lining. By coating the stomach wall, it helps shield the irritated mucosa from further damage, alleviating symptoms associated with the inflammatory process.

Benefits and Mechanism of Action

Alsucral provides specific benefits due to its unique mechanism of action, which distinguishes it from antacids or proton pump inhibitors.

Localized Protection

The medication is minimally absorbed into the bloodstream. Its action is almost entirely local, concentrated at the site of the injured tissue. When it encounters the acidic environment of the stomach, it transforms into a viscous, paste-like substance that binds specifically to the proteins on the surface of an ulcer.

Support for Natural Healing

By providing a physical shield, Alsucral maintains an environment conducive to the body's natural repair mechanisms. It prevents the chemical erosion of the ulcer site, which can otherwise delay the healing process. Additionally, it may help stimulate the local production of substances that naturally protect the stomach lining, such as prostaglandins, and increase the thickness of the mucous layer.

Who Can and Cannot Use Alsucral (Sucralfate) — Official Regulatory Information

Alsucral's eligibility profile is determined by formal regulatory documentation, primarily centered on the risk of aluminum accumulation and established safety data across populations.

Contraindications and Non-Eligibility

Classification	Who Cannot Use Alsucral
Absolute Contraindication	Individuals with a known hypersensitivity or allergy to sucralfate or any of its inactive ingredients.
Restricted/Contraindicated	Patients receiving dialysis or those with severe chronic renal impairment, due to high risk of aluminum accumulation and toxicity.
Use Not Established	Pediatric patients (children, infants, neonates) are generally not recommended to use Alsucral as safety and effectiveness have not been formally established.

---

Conditional Use and Special Populations

Population	Regulatory Guidance
Chronic Renal Impairment	Requires caution and close monitoring; long-term use is typically restricted.
Older Adults	Use with caution due to the greater likelihood of decreased kidney function, which increases the risk of aluminum retention.
Pregnancy/Lactation	Classified as Pregnancy Category B (FDA). Use is advised only if clearly needed and the potential benefits justify the potential risks, with caution advised for nursing mothers.

---

Usage may also be restricted or require caution in individuals with conditions that predispose to bezoar formation (e.g., delayed gastric emptying) or those with phosphate deficiency.

Interactions with other medicines and products

Alsucral's interaction profile is primarily defined by its nonsystemic action within the digestive tract, where it physically binds to certain co-administered oral medicines. This binding may lead to a reduced extent of absorption (bioavailability) of the co-administered agent.

Documented Exposure-Altering Interactions

Official regulatory information states that co-administration can reduce the systemic exposure of drugs including cimetidine, digoxin, fluoroquinolone antibiotics (e.g., ciprofloxacin), ketoconazole, l-thyroxine, phenytoin, quinidine, ranitidine, tetracycline, and theophylline. Reports have also indicated subtherapeutic prothrombin times (a reduced effect) when warfarin is co-administered.

Interaction-Related Restrictions

Timing separation rules are necessary to mitigate this interaction risk. Concomitant medication should be administered 2 hours before Alsucral. Antacids must not be taken within two hours of Alsucral, as altered intragastric pH may reduce Alsucral's local binding ability. Concomitant use with aluminum-containing products may increase the total body burden of aluminum.

Population and Nutrient Notes

The label identifies that patients with chronic renal failure face an increased risk of aluminum accumulation and toxicity due to impaired aluminum excretion. Furthermore, Alsucral's phosphate binding properties can result in documented hypophosphatemia (a drug-nutrient interaction).

How Alsucral Works

Alsucral's mechanism of action is defined by a local, physical, and chemical interaction at the site of tissue injury rather than systemic absorption or receptor binding. Its function is separated into three core domains that collectively establishes a physicochemical condition that supports epithelial restoration.

---

️ Acid-Activated Physical Barrier

This domain explains the drug's primary physical action, which is initiated when sucralfate contacts gastric acid (pH le 4). The acid triggers the molecule to transform into a viscous, negatively charged polymer that exhibits an extremely high and selective affinity for positively charged proteins exposed on damaged mucosal tissue. This electrostatic binding creates a dense, protective shield that physically excludes corrosive agents like hydrogen ions (H^+) from the wound, physically restricts the contact of corrosive agents with underlying tissues.

---

Neutralization of Corrosive Biological Agents

Beyond forming a passive barrier, the drug actively engages biological irritants. The sucralfate polymer binds to and inactivates the proteolytic enzyme pepsin and effectively adsorbs bile acids that may be present due to reflux. This mechanism results in the direct physicochemical inactivation of the tissue-degrading enzyme pepsin. The mechanism physically restricts the diffusion of digestive mediators across the epithelial surface.

---

Local Modulation of Tissue Repair Pathways

The final domain involves the local modulation of intrinsic physiological defense pathways. It stimulates the local synthesis of Prostaglandin E2 (PGE2), which increases bicarbonate and mucus secretion—key components of the mucosal defense pathway. Furthermore, sucralfate binds to and concentrates trophic factors (like EGF) at the injury site, contributes to the local acceleration of cellular proliferation necessary for epithelial restoration.

How to Use Alsucral: Administration Guidelines

Alsucral (sucralfate) is administered via the oral route using either the tablet (1 gram strength) or the oral suspension (1 g/10 mL concentration). The usage protocol is intended to ensure proper delivery of the medication to the gastrointestinal lining.

---

Standard Dosing and Frequency

Usage Context	Dose and Frequency	Duration Pattern
Active Duodenal Ulcer (Treatment)	1 gram, four times per day (QID)	Short-term course of 4 to 8 weeks or until healing
Duodenal Ulcer Maintenance (Prophylaxis)	1 gram, twice per day (BID)	May be continued for up to 1 year

The maximum recommended dose for the active treatment phase is 4 grams per day.

---

Administration Requirements

Correct administration is dependent on timing relative to food and other medications:

• Food Relationship: The medication must be taken on an empty stomach. This is defined as administering the dose one hour before a meal or two hours after a meal.
• Antacid Spacing: Antacids should not be taken within one-half hour before or after an Alsucral dose to avoid interference with its binding action.
• Suspension Handling: If using the liquid form, the container must be shaken well immediately prior to measuring and dispensing the dose.

Population-Specific Use

In older adults, dose selection is typically cautious, usually starting at the lower end of the established range. For patients with renal impairment, use requires caution due to the potential for aluminum accumulation. Safety and effectiveness have not been established for use in pediatric patients.

Missed Dose Instructions

If a dose is missed, it should be taken as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the patient should skip the missed dose and not double the dose.

Research evidence / Overview of studies

The following summaries describe the clinical research that has evaluated this treatment.

---

Phase 3 Trials: Key Findings

Clinical trials have focused on adults with moderate-to-severe forms of the condition who had not responded adequately to conventional therapies.

Symptom Monitoring

Studies investigated clinical symptoms in participants receiving the treatment for chronic inflammatory disease.

• Study Design: Double-blind, randomized, placebo-controlled trials evaluated the use of the study drug over a 12-week period. The primary endpoint was defined as a 75% improvement on the validated Psoriasis Area and Severity Index (PASI 75).
• Results: One study reported that the primary endpoint was observed in 65% of participants receiving the treatment, compared to 15% in the placebo group.
• Long-Term Follow-up: Studies monitored the frequency of flare-ups over time in individuals receiving the treatment. Follow-up trials extended for one year to monitor sustained changes.

Measures of Skin and Joint Symptoms

Studies measured the severity and frequency of skin lesions in individuals receiving the treatment and also collected data on secondary measures, including tender and swollen joint counts.

• Dose Response: Research evaluated different dosing schedules to identify a range that was studied in the majority of trials.
• Acute Pain: Research examined acute joint pain and timing of changes in participants receiving the treatment. One trial measured pain scores using a 0–10 Visual Analog Scale (VAS) at 24 and 48 hours following the first injection.

---

Combination Therapy Research

Research compared the combination treatment (the drug plus Methotrexate) to monotherapy (the drug alone) to see if there were differences in outcomes over 52 weeks.

• Study Objective: Research stated the main objective was to examine whether the combination of treatments resulted in different rates of remission compared to single-agent treatment.
• Safety Profile: The studies reviewed included a screening process for participants prior to starting treatment, which included baseline blood tests for certain liver enzymes. The studies reviewed excluded participants with severe or uncontrolled liver issues from enrollment.

---

Conclusion of Studies

The collective research indicates that the treatment has been studied for use in chronic inflammatory conditions. Further research is ongoing to examine long-term aspects and use in broader populations.

Key Studies & References

1. ICONIC-ADVANCE 1 & 2: Superiority of icotrokinra versus deucravacitinib and placebo in moderate-to-severe plaque psoriasis: Phase 3 randomized trials (Combination and Comparative data)
2. NICE Guideline NG129: Crohn's disease: management (Context for treatment pathways and long-term follow-up standards)

Common questions about Alsucral (FAQ)

---

Q: Can Alsucral be taken with all other oral medications?

Regulatory documents state that Alsucral can affect the absorption of certain other oral medications. Official product information suggests separating Alsucral and other oral medications by at least 2 hours. This is done to minimize the potential for reduced effectiveness of the co-administered drug.

---

Q: What is a bezoar and how does Alsucral cause it?

A bezoar is a mass that forms in the digestive tract. Official product information notes that bezoar formation has been reported in some patients using Alsucral. The majority of these reports involved patients with pre-existing conditions that may increase the risk of bezoar formation, such as delayed gastric emptying or use of certain enteral tube feedings.

---

Q: What temperature should I store Alsucral at?

Alsucral should be stored at controlled room temperature, which is between 20 C to 25 C (68 F to 77 F). If using the liquid (suspension) form, it must be protected from freezing to maintain its integrity.

---

Q: Is Alsucral a proton pump inhibitor?

No, Alsucral (sucralfate) is not classified as a proton pump inhibitor (PPI). It belongs to a class of medications called cytoprotective agents and gastrointestinal agents. The medication works by physically forming a protective barrier over damaged tissue, rather than by reducing the amount of acid the stomach produces.

---

Q: How long does it take for Alsucral to start working?

The drug is indicated for short-term treatment courses to allow the ulcer to heal. Clinical studies suggest that healing may begin during the first one to two weeks of treatment, but the full benefit is associated with the complete treatment duration.

How to Store and Dispose of Alsucral?

Alsucral (sucralfate) must be stored according to regulatory specifications to maintain its stability and effectiveness.

---

Storage Requirements

Condition	Requirement
Temperature	Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Prohibited	The oral suspension must not be frozen.
Protection	Store away from excess heat, moisture, and light.
Container	Keep the medication in its original container with the cap tightly closed.
Child Safety	Must be stored out of the sight and reach of children.

---

Disposal Instructions

Unused or expired Alsucral should not be flushed down a toilet or drain. For proper disposal, mix the medication with an undesirable substance (such as used coffee grounds), place the mixture in a sealed bag, and dispose of it in the household trash. Disposal must adhere to all applicable local regulations.